


**Product Name** : Ponatinib  
**Cat. No.** : PC-42862  
**CAS No.** : 943319-70-8  
**Molecular Formula** : C<sub>29</sub>H<sub>27</sub>F<sub>3</sub>N<sub>6</sub>O  
**Molecular Weight** : 532.5595  
**Target** : Bcr-Abl  
**Solubility** : DMSO: ≥ 50 mg/mL



## Biological Activity

Ponatinib (AP 24534) is a potent, orally active pan-inhibitor of **BCR-ABL** kinase with IC<sub>50</sub> of 0.37 and 2.0 nM for ABL and mutant ABLT315I, respectively.

Ponatinib retains high potency against other ABL mutants Q252H, Y253F, M351T and H396P (IC<sub>50</sub>s < 0.5 nM), also inhibits c-Src, Lyn, c-KIT, VEGFR2, FGFR1, PDGFRα (IC<sub>50</sub>s = 0.2–5 nM).

Ponatinib inhibits the growth of cells expressing native or mutant BCR-ABL (IC<sub>50</sub>s = 0.5–36 nM).

Ponatinib suppresses BCR-ABL(T315I)-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens.

## References

Gozgit JM, et al. *Mol Cancer Ther.* 2011 Jun;10(6):1028-35.

Huang WS, et al. *J Med Chem.* 2010 Jun 24;53(12):4701-19.

O'Hare T, et al. *Cancer Cell.* 2009 Nov 6;16(5):401-12.

Gozgit JM, et al. *Mol Cancer Ther.* 2012 Mar;11(3):690-9.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com